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Abstract
Introduction: Recently a novel cryoballoon system (POLARx, Boston Scientific)
became available for the treatment of atrial fibrillation. This cryoballoon is com-
parable with Arctic Front Advance Pro (AFA‐Pro, Medtronic), however, it maintains
a constant balloon pressure. We compared the procedural efficacy and biophysical
characteristics of both systems.
Methods: One hundred and ten consecutive patients who underwent first‐time
cryoballoon ablation (POLARx: n = 57; AFA‐Pro: n = 53) were included in this pro-
spective cohort study.
Results: Acute isolation was achieved in 99.8% of all pulmonary veins (POLARx:
99.5% vs. AFA‐Pro: 100%, p = 1.00). Total procedure time (81 vs. 67min, p < .001)
and balloon in body time (51 vs. 35min, p < .001) were longer with POLARx. After a
learning curve, these times were similar. Cryoablation with POLARx was associated
with shorter time to balloon temperature −30°C (27 vs. 31 s, p < .001) and −40°C
(32 vs. 54 s, p < .001), lower balloon nadir temperature (−55°C vs. −47°C, p < .001),
and longer thawing time till 0°C (16 vs. 9 s, p < .001). There were no differences in
time‐to‐isolation (TTI; POLARx: 45 s vs. AFA‐Pro 43 s, p = .441), however, POLARx
was associated with a lower balloon temperature at TTI (−46°C vs. −37°C, p < .001).
Factors associated with acute isolation differed between groups. The incidence of
phrenic nerve palsy was comparable (POLARx: 3.5% vs. AFA‐Pro: 3.7%).
Conclusion: The novel cryoballoon is comparable to AFA‐Pro and requires only a
short learning curve to get used to the slightly different handling. It was associated
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with faster cooling rates and lower balloon temperatures but TTI was similar to
AFA‐Pro.
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1 | INTRODUCTION
The cornerstone of atrial fibrillation (AF) ablation is complete isolation of
the pulmonary veins (PVs).1 Among the different available single‐shot
devices, the cryoballoon has demonstrated to be as effective and safe as
radiofrequency ablation for achieving pulmonary vein isolation (PVI),
while being associated with shorter procedure duration and longer
fluoroscopy time.2–7 Furthermore, cryoballoon ablation seems to be less
operator‐dependent than radiofrequency ablation.8 Recently, a novel
cryoballoon was introduced, the POLARx cryoablation system (Boston
Scientific). The unique feature of this cryoballoon is that it maintains a
uniform pressure and size during inflation and cryoablation. Theoretically,
a more compliant balloon can improve PV occlusion resulting in a more
effective cryoenergy delivery. Currently, limited data exists on the
biophysical characteristics of this novel cryoballoon.9 Knowledge of
biophysical parameters, such as nadir balloon temperature and balloon
thawing time, is important as they have been shown to be associated
with durability of PVI after cryoballoon ablation.10–12
1.1 | Aim of the study
The aim of this study was to compare the procedural efficacy and
biophysical parameters of the novel POLARx system (Boston
Scientific) with the currently established fourth‐generation Arctic
Front Advance Pro system (AFA‐Pro, Medtronic).
2 | METHODS
2.1 | Study population
In this prospective cohort study, we included consecutive patients
who underwent a first‐time cryoballoon ablation for the treatment of
symptomatic paroxysmal or persistent AF between May and October
2020. Starting in May 2020, there was a limited market release of
the POLARx cryoablation system in Europe. Patients were included
from three highly experienced cryoballoon ablation centers. The
study was approved by the institutional review board of each center.
2.2 | Periprocedural management
All patients received oral anticoagulation for at least 4 weeks before
ablation. Periprocedural anticoagulation regime was carried out
according to the local standards. To exclude left atrial thrombi, all
patients underwent transesophageal echocardiogram within 24 h of
the procedure or by intracardiac echocardiography before trans-
septal puncture.
2.3 | Ablation procedure
All procedures were performed with local anesthesia and analgose-
dation. After vascular access was obtained, a single transseptal
puncture was performed. Intravenous heparin was administered to
achieve a target activated clotting time of more than or equal to
300 s. All patients underwent PVI using a 28‐mm cryoballoon
(AFA‐Pro [8‐mm tip], Medtronic; or POLARx [short tip: 5‐mm tip or
long tip: 12‐mm tip, Boston Scientific]; Figure 1). The balloon was
inserted through a steerable sheath (15‐F FlexCath, Medtronic; or
15.9‐F POLARSHEATH, Boston Scientific). PV potentials were
recorded using a 20‐mm circular inner lumen mapping catheter with
8 electrodes (Achieve, Medtronic; or POLARMAP, Boston Scientific).
After optimal PV occlusion was achieved, assessed by contrast
injection, cryoablation was started. A time‐to‐isolation (TTI) guided
ablation protocol was used. The freeze duration was 180 s if TTI was
less than 60 s, otherwise a 240‐s freeze cycle was employed. No
bonus freeze was employed routinely. PVI was confirmed by
entrance/exit block at the end of the procedure.
During cryoablation of the right‐sided PVs, either breathing
maneuvers or high‐output right phrenic nerve stimulation was
performed using a diagnostic catheter in the right subclavian vein or
superior vena cava. Diaphragmatic excursion was assessed by pal-
pation or, in case of the POLARx system, by using the Diaphragmatic
Movement Sensor (DMS). The DMS uses an accelerometer and
provides a relative measure of the diaphragmatic excursion.
Whenever the diaphragmatic excursions decreased or the DMS
percentage drops below a cutoff (65%), cryoablation was im-
mediately terminated. During cryoablation of the left‐sided PVs, a
diagnostic catheter was placed in the right ventricle to provide
ventricular pacing in case of a vagal response after cryoablation.
2.4 | Data collection
Patient demographic and clinical data were obtained from the
medical records. A case report form was used to capture all relevant
procedural and biophysical data. For every cryoballoon application
(CBA) the following parameters were collected: grade of PV
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occlusion (Grades 1–4),13 the presence of PV potential during abla-
tion, duration of CBA, TTI (if measurable), balloon temperature at
TTI, time to balloon temperature −30°C, time to balloon temperature
−40°C, balloon nadir temperature, and thawing time till 0°C. The last
parameter was defined as the time needed for the balloon to rewarm
till 0°C upon completion of the CBA. This thawing parameter was
chosen because a previous study demonstrated that a thawing time
till 0°C more than or equal to 10 s predicts durable PVI after cryo-
balloon ablation with the second‐generation cryoballoon (Arctic
Front Advance, Medtronic).10 TTI was defined as the time duration
required to achieve PVI after start of CBA. All time variables were
expressed in seconds.
With the AFA‐Pro cryoballoon system, TTI was manually re-
corded after achieving PVI. The cryoablation binary data files stored
in the CryoConsole (Medtronic) were used to analyze various bio-
physical parameters (i.e., balloon temperature at TTI, time to balloon
temperature −30°C, time to balloon temperature −40°C, nadir bal-
loon temperature, and thawing time till 0°C).
With the POLARx cryoballoon system, TTI could be annotated
by the operator during the CBA by pressing the foot pedal for 3 s.
Most biophysical data can be exported from the SMARTFREEZE
console (Boston Scientific) onto a pdf‐file (i.e., TTI, time to balloon
temperature −30°C, time to balloon temperature −40°C, nadir bal-
loon temperature, and thawing time till 0°C). Only balloon tem-
perature at TTI had to be collected from the cryoablation binary data
files from the SMARTFREEZE console (Boston Scientific).
2.5 | Follow‐up
All patients were followed up for at least 1 month after the proce-
dure to collect data on acute procedural complications and mainly to
rule out atrioesophageal fistula. Patients with phrenic nerve palsy
underwent a chest x‐ray during follow‐up. Patients who developed
pulmonary symptoms underwent a cardiac computed tomography to
rule out complications. Antiarrhythmic drugs were stopped at the
discretion of the operator.
2.6 | Statistical method
Continuous data are presented as median with 25th and 75th per-
centile as the data were not normally distributed. Categorical vari-
ables are presented by frequencies and percentages. Differences of
continuous variables between the two groups were analyzed with
the nonparametric Mann–Whitney U‐test. Differences between ca-
tegorical variables were evaluated using the χ2 test or Fisher′s exact
test. Statistical analyses were performed using MATLAB R2020a. All
statistical tests were two‐sided. p values less than .05 were con-
sidered statistically significant.
3 | RESULTS
3.1 | Study population
In the study period, 110 consecutive patients underwent a first cryo-
balloon ablation for the treatment of AF. The POLARx and AFA‐Pro
system was used in 57 and 53 patients, respectively. The short‐tip
POLARX balloon was used in the majority (93.0%) of the cases in the
POLARx group. Baseline patient characteristics are presented in
Table 1. The POLARx group had a lower proportion of patients with
hypertension and a higher proportion of patients using a DOAC in
comparison with the AFA‐Pro group. The use of antiarrhythmic drug
therapy was more common in the AFA‐Pro group. Other baseline
variables were similar between groups, including age, sex, type of AF,
CHA2DS2‐VASc score, left ventricular ejection fraction, and left atrial
dimension. The majority of patients had paroxysmal AF (75.5%).
F IGURE 1 Cine‐images of both cryoballoons during PV occlusion. (A) 28‐mm POLARx cryoballoon with 5mm tip, POLARMAP circular
mapping catheter and 15.9F POLARSHEATH; (B) 28‐mm AFA‐Pro cryoballoon with 8mm tip, Achieve circular mapping catheter and 15F
FlexCath
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3.2 | Procedural efficacy
A total of 422 PVs was targeted (POLARx: n = 216, AFA‐Pro:
n = 206). Acute isolation was achieved in 99.8% of all PVs, and was
similar between groups (POLARx: 99.5% vs. AFA‐Pro: 100%,
p = 1.00). One left superior PV (diameter of 15mm on CT‐scan) could
not be isolated in the POLARx group despite four CBAs with Grade 4
occlusion. Procedure‐related variables are presented in Table 2.
Procedure time and balloon in body time were longer, and the
amount of contrast agent used was higher in the POLARx group in
comparison with the AFA‐Pro group. Other procedure‐related vari-
ables, including the median number of CBA per patient, fluoroscopy
time, radiation dose, and additional CTI ablation were similar be-
tween groups (Table 2).
A learning curve analysis was performed with regard to proce-
dural parameters. Analysis of the second half of the cohort showed
no difference in procedure time (POLARx: 78 [63–95] min vs. AFA‐
Pro: 75 [53–85] min, p = .149), balloon in body time (POLARx: 43
[38–61] min vs. AFA‐Pro: 38 [31–44] min, p = .066), and contrast dye
usage (POLARx: 50 [40–65] ml vs. AFA‐Pro: 43 [36–50] ml, p = .063).
3.3 | Comparison of procedural and biophysical
parameters between groups
There was no difference in the magnitude of PV occlusion between
groups (Table 3). In the majority of cases a Grade 4 occlusion could
be achieved. Cryoablation with POLARx was associated with a
shorter time to balloon temperature −30°C and −40°C, a lower
balloon nadir temperature, and a longer thawing time till 0°C. PV
potentials could be recorded more often during CBA with POLARx
than with AFA‐Pro (96.3% vs. 88.6%, p < .001). TTI could be recorded
in 93.1% of PVs using POLARx versus 79.6% using AFA‐Pro
(p < .001). There were no differences in TTI between systems, how-
ever, POLARx was associated with a lower balloon temperature at
TTI in comparison with AFA‐Pro. Detailed information with regard to
balloon nadir temperature and thawing time till 0°C for each PV is
presented in Figure 2. POLARx was associated with a lower balloon
nadir temperature and longer thawing time till 0°C for each PV in
comparison with AFA‐Pro.
3.4 | Procedural and biophysical parameters
associated with acute PVI
A comparison of procedural and biophysical parameters of CBAs
resulting in acute PVI or no acute PVI per system is provided in
Table 4. With POLARx, CBAs resulting in acute PVI were associated
with higher grade of PV occlusion, lower balloon nadir temperatures,
and longer thawing times till 0°C in comparison with CBAs resulting
in no acute PVI. Cooling rates till −30°C or −40°C were not pre-
dictive of acute PVI when using POLARx. With AFA‐Pro, CBAs re-
sulting in acute PVI were associated with faster cooling rates till
−30°C or −40°C, lower balloon nadir temperatures, and longer
thawing times till 0°C in comparison with CBAs resulting in no
acute PVI.
3.5 | Complications
Overall, the incidence of complications was low in both groups. One
groin hematoma occurred in the POLARx group which was treated
conservatively. Two phrenic nerve palsies were recognized in each
group, which did not recover at hospital discharge (Table 2). One
patient in the POLARx group experienced a moderate left sided
hemiparesis due to a transient ischemic attack after the procedure.
CT and MRI imaging showed no demarcation of infarct areas. The
patient fully recovered within 24 h without further treatment. There
were no cases of cardiac tamponade, stroke, atrioesophageal fistula,
and death during short‐term follow‐up.
4 | DISCUSSION
Cryoballoon ablation has established itself as an alternative techni-
que to radiofrequency ablation for the treatment of patients with
symptomatic AF.14 Several randomized trials have shown non-
inferiority with respect to efficacy and safety of the first‐ and
second‐generation cryoballoon systems in comparison with radio-
frequency ablation.2–5 The fourth‐generation cryoballoon (AFA‐Pro,





(n = 53) p‐value
Age, years 61 (57, 66) 64 (57, 70) .082
Male sex 33 (57.9%) 36 (67.9%) .326
Hypertension 18 (31.6%) 31(58.5%) .007
Diabetes 3 (5.3%) 3 (5.6%) 1.000
Coronary artery
disease
8 (14.0%) 5 (9.4%) .560
CABG 2 (3.5%) 1 (1.9%) 1.000
Paroxysmal AF 43 (75.4%) 40 (75.5%) 1.000
LVEF (%) 63 (60, 65) 60 (60, 65) .813
LA diameter, mm 41 (36, 44) 41 (37, 43) .732
CHA2DS2‐VASc score 1 (1, 2) 2 (0, 3) .533
Vitamin K antagonist 3 (5.7%) .109
DOAC 57 (100.0%) 48 (90.6%) .023
Antiarrhythmic drugs 30 (52.6%) 40 (75.5%) .017
Note: Values are presented as median (25th, 75th percentile) or as
count (%).
Abbreviations: AF, atrial fibrillation; AFA‐Pro, Arctic Front Advance Pro;
CABG, coronary artery bypass graft; DOAC, direct‐acting oral
anticoagulant; LA, left atrium; LVEF, left ventricular ejection fraction.
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Medtronic) has a 40% shorter distal tip (8 mm) which improves real‐
time measurement of PVI. This has resulted in fewer CBAs, shorter
balloon in body times and shorter procedure times in comparison to
the second‐generation cryoballoon.15
Recently, a novel cryoballoon system, POLARx (Boston
Scientific), became commercially available. Similar to AFA‐Pro, it
consists of a double‐layer balloon of 28 mm and has eight re-
frigerant injection ports resulting in cooling of the entire distal
half of its surface. Furthermore, the location of the thermocouple
of the POLARx cryoballoon is similar to AFA‐Pro (21.5 mm be-
tween thermocouple and injection coil),16,17 thus, measurements
of inner balloon temperatures should be similar. The main dif-
ference between the two cryoballoon technologies is the con-
stant pressure inside the POLARx balloon. The pressure of the
POLARx is comparable with AFA‐Pro in an inflated, nonfrozen
state. However, with the POLARx balloon, the pressure is kept
constant even during the freeze.
Although the basic principles between both cryoablation sys-
tems are similar, we did observe a learning curve effect in our study.
This can be explained by the different new features of the POLARx
platform which required some time to become familiar with it. Be-
sides changes in hardware (i.e., detailed console interface, foot pedal
option, different catheter handle design, and more flexible sheath),
the approach to achieve pulmonary vein occlusion is different than
with AFA‐Pro. The constant balloon pressure results in a more
compliant cryoballoon. To achieve optimal PV occlusion the cryo-
balloon should be co‐axially aligned with the PV and minimal forward
push should be used. Excessive push may result in a too distal pla-
cement of the cryoballoon which will not be compensated by a pop‐
out phenomenon. This is especially true for ablations of the right
sided PVs to avoid phrenic nerve palsy. An advantage of the constant
balloon pressure and compliant balloon is that deformations caused
by pushing the balloon to obtain a good occlusion grade will be kept
in size and shape during the freeze with POLARx. In addition, a more
compliant balloon could theoretically provide a better balloon‐tissue
contact.
Balloon‐tissue contact is important to achieve an optimal effect
of cryoballoon ablation. The magnitude of PV occlusion as visualized
by PV angiography is a practical marker of optimal balloon‐tissue
contact and is a predictor of a durable PVI.10 In clinical practice, the
aim is to achieve a Grade 4 PV occlusion before starting cryoabla-
tion. In our study, there was no difference in the degree of PV oc-
clusion achieved during CBA between POLARx and AFA‐Pro. For
both systems, CBAs resulting in acute PVI were associated with a
TABLE 2 Procedural and clinical
outcomes
Variables POLARx (n = 57) AFA‐Pro (n = 53) p‐value
Procedural
Procedure time, min 81 (70, 95) 67 (49, 83) <.001
Balloon in body time, min 51 (41, 62) 35 (31, 42) <.001
Fluoroscopy time, min 14.0 (9.8, 18.3) 10.8 (8.1, 16.1) .141
Radiation dose, cGy*cm2 637 (375, 1133) 686 (358, 1083) .817
Contrast agent, ml 50 (40, 60) 40 (25, 50) .002
Number of CBA per patient 5 (4, 6) 5 (4, 6) .339
Left common ostium PV 12 (23.1%) 6 (12.5%) .203
Total duration CBA, s 995 (870, 1.262) 912 (821, 1.173) .277
Duration CBA LSPV, s 209 (180, 289) 180(180, 240) .553
Duration CBA LIPV, s 180 (180, 240) 180 (180, 249) .500
Duration CBA RSPV, s 240 (180, 277) 180 (180, 240) .466
Duration CBA RIPV, s 180 (180, 240) 180 (180, 240) .171
Duration CBA LCPV, s 240 (180, 240) 240 (210, 367) .373
Additional CTI ablation 3 (5.3%) 7 (13.2%) .192
Acute procedural complications
Groin hematoma 1 (1.8%) 0 (0%) 1.000
Phrenic nerve palsy 2 (3.5%) 2 (3.7%) 1.000
TIA 1 (1.8%) 0 (0%) 1.000
Note Values are presented as median (25th, 75th percentile) or as count (%).
Abbreviations: AF, atrial fibrillation; AFA‐Pro, Arctic Front Advance Pro; CBA, cryoballoon
application; CTI, cavotricuspid isthmus; LIPV, left inferior pulmonary vein; LSPV, left superior
pulmonary vein; PV, pulmonary vein, RIPV, right inferior pulmonary vein; RSPV, right superior
pulmonary vein; TIA, transient ischemic attack.
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higher proportion of Grade 4 PV occlusion in comparison with CBAs
without acute PVI.
Several studies have shown that TTI is the most powerful pre-
dictor of durable PV isolation.10,18–21 In clinical practice, a TTI less
than or equal to 60 s is the target for CBA. In our study, there was no
difference in the median TTI between both systems and the median
TTI was less than or equal to 60 s. This suggests that the speed of
cryoenergy transfer to the atrial tissue is similar between both sys-
tems. Interestingly, TTI could be recorded in a higher percentage of
PVs with POLARx than with AFA‐Pro (93.1% vs. 79.6%). This dif-
ference may be explained by the shorter distal tip of POLARx (5mm)
in comparison to AFA‐Pro (8mm), which brings the circular mapping
catheter closer to the PV ostium. Furthermore, there is an additional
insulation of the core wire in POLARMAP (circular mapping catheter)
which allows an increase in recording gain without jeopardizing the
quality of the signal (higher signal‐to‐noise ratio).
Several biophysical parameters have been evaluated as possible
predictors of durable PV isolation, such as balloon cooling rates,
balloon nadir temperature, and balloon thawing times.10–12 Previous
studies have shown that the most reliable biophysical marker of
durable PVI is the balloon thawing time with the first‐ and second‐
generation cryoballoon (Arctic Front and Arctic Front Advance,
Medtronic).10,12 Longer thawing times may not only represent colder
CBA but also more effective CBA. A longer thawing time is believed
to promote additional cellular injury.10,22 The present study showed
that the POLARx system has a longer thawing time till 0°C than
AFA‐Pro. Whether this translates into a higher prevalence of durable
PV isolation with POLARx is unknown and requires further
investigation.
In our study, the POLARx system achieves faster balloon cooling
rates and lower balloon nadir temperatures than AFA‐Pro. However,
cooling rates till −30°C or −40°C was not associated with acute PVI
with POLARx in contrast to AFA‐Pro. TTI was comparable between
systems, despite lower balloon temperatures at TTI (difference of
approximately 10°C) with the POLARx system. Balloon nadir tem-
peratures was associated with acute PVI with both systems. Previous
studies have shown that the balloon nadir temperature is a weak
indicator for durable PVI and cooling rates are not predictive for
durable PVI with the second‐generation cryoballoon (Arctic Front
TABLE 3 Comparison of procedural and biophysical parameters
between POLARx and AFA‐Pro
Variables POLARx AFA‐Pro p‐value
Total number of CBAa 299 264
Grade of PV occlusion .206
Grade 4 244 (81.6%) 204 (77.3%)
Grade 3 52 (17.4%) 57 (21,6%)
Grade 2 3 (1.0%) 3 (1.1%)
Time to balloon temperature
−30°C, s
27 (25, 30) 31 (28, 37) <.001
Time to balloon temperature
−40°C, s
32 (30, 38) 54 (45, 75) <.001
Balloon nadir
temperature (°C)
−55 (‐60, ‐51) −47 (‐52, ‐43) <.001
Thawing time to 0°C, s 16 (13, 20) 9 (7, 11) <.001
PVP visible during CBA 288 (96.3%) 234 (88.6%) <.001
TTI recorded during CBA 208 (69.6%) 167 (63.3%) .117
TTI, s 45 (33, 69) 43 (30, 66) .441
Balloon temperature at
TTI (°C)
−46 (‐51, ‐40) −37 (‐41, −30) <.001
Total number of PVs 216 206
TTI measured per PV 201 (93.1%) 164 (79.6%) <.001
Note: Values are presented as median (25th, 75th percentile) or as
count (%).
Abbreviations: AF, atrial fibrillation; AFA‐Pro, Arctic Front Advance
Pro; CBA, cryoballoon application; PV, pulmonary vein; PVP, pulmonary
vein potential; TTI, time to isolation.
aOnly CBA>100s was incorporated in the data.
F IGURE 2 Balloon nadir temperature (A) and thawing time till
0°C (B) per pulmonary vein. AFA, Arctic Front Advance; LIPV, left
inferior pulmonary vein; LSPV, left superior pulmonary vein;
RIPV, right inferior pulmonary vein; RSPV, right superior pulmonary vein
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Advance, Medtronic).10,12 Balloon temperatures provide an im-
precise reflection of the target atrial tissue temperatures. This is not
surprising as it depends on many factors including balloon position-
ing within the PV ostium, balloon‐to‐PV size ratio, and ipsilateral PV
blood flow. Furthermore, although the location of the thermocouple
is similar between both POLARx and AFA‐Pro, we cannot exclude
the possibility that the more compliant balloon of POLARx may bring
the thermocouple closer to the cooling area than AFA‐Pro resulting
in lower balloon temperatures.
4.1 | Study limitations
First, the data acquired from the POLARx system was based on our
initial experience with this novel cryoballoon system. Although the
general workflow of the procedure is similar to the AFA‐Pro system,
there are small differences with regard to the approach to achieve
optimal PV occlusion. This is reflected by the longer procedure and
balloon in body times with the POLARx system which improved
during the second phase of the study. Despite the effect of the
learning curve, the total number of CBAs was similar between sys-
tems. Second, this was a nonrandomized observational study with its
inherent limitations. To prevent selection bias, we used consecutive
patients who underwent cryoballoon ablation. There were no sig-
nificant differences in baseline variables with regard to age, sex, type
of AF, and left atrial dimensions. Third, we did not systematically
measure esophageal temperatures during cryoablation. Therefore,
we cannot comment on the effect of the lower balloon temperatures
of the POLARx system on the luminal esophageal temperature.
Fourth, subclinical complications such as esophageal ulceration or PV
stenosis could not be excluded, since routine diagnostic studies were
not performed to investigate such complications. However, during
the 1‐month follow‐up, there was no evidence of symptoms related
to esophageal irritation. Lastly, we don't have information on the
durability of PVI, therefore we cannot comment which biophysical
parameter predicts a durable PVI with the POLARx cryoablation
system.
5 | CONCLUSION
The novel POLARx cryoballoon is comparable with AFA‐Pro with
regard to efficacy and safety. Accordingly, a short learning curve is
required to get used to the slightly different handling due to the
compliant nature of the balloon. POLARx was associated with faster
cooling rates and lower balloon temperatures but TTI was similar in
both groups.
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TABLE 4 Procedural and biophysical parameters associated with acute PVI per CBA
POLARx AFA‐Pro
Variables CBA with PVI CBA without PVI p‐value CBA with PVI CBA without PVI p‐value
Total number of CBAa 232 67 214 50 .349
Grade of PV occlusion
Grade 4 208 (89.7%) 36 (53.7%) <.001 174 (81.3%) 30 (60.0%) <.001
Grade 3 22 (9.5%) 30 (44.8%) <.001 39 (18.2%) 18 (36.0%) .006
Grade 2 2 (0.9%) 1 (1.5%) .53 1 (0.5%) 2 (4.0%) .093
Time to balloon temperature −30°C, s 27 (25, 30) 27 (25, 30) .807 30 (28, 35) 37 (31, 40) <.001
Time to balloon temperature −40°C, s 32 (30, 38) 33 (30, 38) .430 53 (43, 72) 66 (52, 91) .015
Balloon nadir temperatureCB (°C) −57 (−61, −53) −50 (−54, −47) <.001 −48 (−53, −45) −43 (−47, −39) <.001
Thawing time to 0°C, s 17 (14, 22) 13 (10, 14) <.001 9 (8, 12) 6 (5, 8) <.001
Note: Values are presented as median (25th, 75th percentile) or as count (%).
Abbreviations: AFA‐Pro, Arctic Front Advance Pro; CBA, cryoballoon application; PVI, pulmonary vein isolation.
aOnly CBA>100 s was incorporated in the data.
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